Ізраїль - іврит - Ministry of Health

unipharm ltd, israel - amlodipine as besilate; valsartan - טבליות מצופות - valsartan 160 mg; amlodipine as besilate 5 mg - valsartan

Ізраїль - іврит - Ministry of Health

unipharm ltd, israel - amlodipine as besilate; valsartan - טבליות מצופות - valsartan 80 mg; amlodipine as besilate 5 mg - valsartan

Ізраїль - іврит - Ministry of Health

unipharm ltd, israel - amlodipine as besilate; valsartan - טבליות מצופות - valsartan 80 mg; amlodipine as besilate 5 mg - valsartan

Ізраїль - іврит - Ministry of Health

unipharm ltd, israel - hydrochlorothiazide; losartan potassium - טבליה - losartan potassium 50 mg; hydrochlorothiazide 12.5 mg

Ізраїль - іврит - Ministry of Health

unipharm ltd, israel - hydrochlorothiazide; losartan potassium - טבליה - losartan potassium 50 mg; hydrochlorothiazide 12.5 mg

Ізраїль - іврит - Ministry of Health

bioavenir ltd - losartan as potassium 50 mg - tablets - losartan - hypertension: losartan is indicated for the treatment of heart failure ( nyha ii and iii) usually in addition to diuretics and/or digitalis if use of an ace inhibitor is not appropriate. switching patients with heart failure who are stable on an ace inhibitor to tiasar is not recommended. renal protection in type - 2 diabetic patients with proteinuria: losartan is indicated to delay the progression of renal disease as measured by a reduction in the combined incidence of doubling of serum creatinine end stage renal disease ( need for dialysis or renal transplantation) or death and to reduce proteinuria. reduction in the risk of cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrphy. losartan is indicated to reduce the risk of cardiovascular morbidity and mortality as measured by the combined incidence of cardiovascular death stroke and myocardial infarction in hypertensive patients with left ventricular hypertrphy. the benefit of tiasar on the primary deposite end poin

Ізраїль - іврит - Ministry of Health

bioavenir ltd - losartan as potassium 100 mg - tablets - losartan - hypertension: losartan is indicated for the treatment of heart failure ( nyha ii and iii) usually in addition to diuretics and/or digitalis if use of an ace inhibitor is not appropriate. switching patients with heart failure who are stable on an ace inhibitor to tiasar is not recommended. renal protection in type - 2 diabetic patients with proteinuria: losartan is indicated to delay the progression of renal disease as measured by a reduction in the combined incidence of doubling of serum creatinine end stage renal disease ( need for dialysis or renal transplantation) or death and to reduce proteinuria. reduction in the risk of cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrphy. losartan is indicated to reduce the risk of cardiovascular morbidity and mortality as measured by the combined incidence of cardiovascular death stroke and myocardial infarction in hypertensive patients with left ventricular hypertrphy. the benefit of tiasar on the primary deposite end poin

Ізраїль - іврит - Ministry of Health

sanofi israel ltd - hydrochlorothiazide; ramipril - טבליה - ramipril 2.5 mg; hydrochlorothiazide 12.5 mg - ramipril and diuretics - ramipril and diuretics - essential hypertension. tritace comp is indicated in patients whose blood pressure cannot be adequately lowered with ramipril alone.

Ізраїль - іврит - Ministry of Health

sanofi israel ltd - hydrochlorothiazide; ramipril - טבליה - ramipril 5 mg; hydrochlorothiazide 25 mg - ramipril and diuretics - ramipril and diuretics - essential hypertension. tritace comp is indicated in patients whose blood pressure cannot be adequately lowered with ramipril alone.

Ізраїль - іврит - Ministry of Health

merck sharp & dohme israel ltd - losartan potassium 12.5 mg - tablets - losartan - hypertension: ocsaar is indicated for the treatment of hypertension. heart failure: ocsaar is indicated for the treatment of heart failure (nyha ii) when treatment with an ace inhibitor is no longer considered appropriate. switching patients with heart failure who are stable on an ace inhibitor to ocsaar is not recommended.